Quinoclamine is a naphthoquinone derivative with antitumor activity; it acts as an NF-κB inhibitor, induces differentiation of U-937 cells into macrophage-like cells, suppresses NF-κB activity in HepG2, lung, and breast cancer cell lines by inhibiting IκB-α phosphorylation and p65 translocation, and modulates the expression of genes involved in cell cycle, apoptosis, and phase II drug metabolism (e.g., UDP-glucuronosyltransferase genes).